Neuralink to Launch Voice Decoding Clinical Trial in October; LePu Medical Partners with Hanhai Info

1. Comprehensive Pilot Zones for Data Elements to Pioneer Trials in More Fields

Recently, the National Data Administration stated at a press conference that a major task in the development of comprehensive pilot zones for data elements is to explore new pathways for market-based allocation reforms through bold reforms and pioneering initiatives. Moving forward, the National Data Administration will support these pilot zones in expanding their pioneering efforts across more sectors, thereby exploring additional innovative approaches to advancing the marketization and valorization of data. The initial progress achieved in the construction of comprehensive pilot zones for data elements can be summarized as “three batches”: implementing a batch of highly innovative reform measures, developing a batch of replicable and scalable best practices, and resolving a batch of critical bottlenecks hindering the release of data value. (China Industrial Economic Information Network)

2. Jiangsu Province Strengthens Intellectual Property Protection in the Field of Centralized Drug Procurement

Recently, the Jiangsu Provincial Intellectual Property Office and the Jiangsu Provincial Healthcare Security Administration jointly established working mechanisms for information sharing, dispute resolution, and operational safeguards to further strengthen intellectual property protection in the pharmaceutical procurement sector. When participating in centralized volume-based procurement in Jiangsu Province or applying for "sunshine listing" transactions for their products on the Jiangsu Provincial Drug and Medical Consumables Procurement Management System, enterprises must independently commit that the relevant products do not violate the Patent Law of the People's Republic of China and other applicable laws and regulations. Enterprises are responsible for the authenticity and accuracy of such commitments. If an enterprise fails to make a required commitment or submits false commitments through fraudulent means, its listing or winning bidder status will be suspended. In serious cases, the product’s listing or winning bidder status will be revoked, and penalty points will be assigned and handled in accordance with the relevant provisions of Jiangsu Province’s sunshine procurement credit scoring management system. (Jiangsu Provincial Healthcare Security Administration)

3. The Key Special Project of the National Key R&D Program Officially Approved for Launch

Recently, the kickoff meeting and implementation plan review for the key project “Research on High-Efficiency and High-Stability Sequencing Enzymes and Reagent Systems,” under the National Key R&D Program’s special initiative on “Integration of Biotechnology and Information Technology (BT-IT Integration),” was successfully held at the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences. Led by the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, the project involves collaborative efforts from five institutions, including Beijing Qitan Technology Co., Ltd., Shenzhen Zhenmai Biotechnology Co., Ltd., Wuhan Hanhai New Enzyme Biotechnology Co., Ltd., and Suzhou Guoke Xingan Medical Technology Co., Ltd. Addressing major national emergency needs, the project focuses on resolving critical bottlenecks in sequencing enzymes and reagent systems, thereby supporting the autonomous controllability and iterative upgrading of sequencing technologies. (CACLP In Vitro Diagnostics News)

4. Unveiling of the AI-Agent International Institute for Robotic Intelligence Innovation

Recently, at the 9th Ruijin International Thoracic Surgery Forum held in Shanghai, the “AI-Agent” International Institute for Robotic Intelligence Innovation and Training Center was unveiled. The institute is dedicated to integrating clinical medicine, engineering, and artificial intelligence technologies, with a focus on interdisciplinary innovation and clinical translation in areas such as thoracic surgical robots, intelligent auxiliary diagnosis and treatment systems, and precise perioperative decision-making. This international institute not only aims to promote AI-enabled healthcare but also serves as a training center. Leveraging its cutting-edge achievements, it will establish a tripartite talent development system that combines virtual simulation drills, hands-on clinical training, and specialized continuing education. By providing systematic training for surgeons, engineers, and researchers, the institute seeks to advance the standardized application and widespread adoption of intelligent surgical technologies. (Wenhui Daily)

5. 51 Hospitals in Guangdong “Weave a Network” to Collaborate in Blocking the “Eraser of Memory”

Recently, at the themed promotional event for World Alzheimer’s Month 2025 in Guangdong Province, a collaboration network was officially launched. Three hospitals—Zhujiang Hospital of Southern Medical University, Guangdong Second Provincial General Hospital, and the Second Affiliated Hospital of Guangzhou Medical University—were designated as provincial-level guiding institutions, while 48 medical institutions were appointed as provincial-level member units. Additionally, 21 municipal-level guiding institutions and more than 500 municipal, county, and grassroots member units were identified. These entities will collaboratively explore a whole-course management service model for dementia in older adults that integrates medical care with prevention and combines traditional Chinese medicine with Western medicine, thereby continuously improving the accessibility, convenience, and continuity of healthcare services. Moving forward, Guangdong will roll out the “Implementation Plan for Guangdong Province’s Response to the National Action Plan on Dementia in Older Adults,” fully implementing the national action plan. The prevention and treatment of dementia in older adults will be prioritized as a key task, with efforts focused on enhancing diagnostic and therapeutic capabilities and building a dementia-friendly social environment. (Yiou.com)

6. Elon Musk’s Neuralink Plans to Launch Speech Trials

Neuralink, Elon Musk’s brain-computer interface company, plans to launch a clinical trial in the United States this October. The trial aims to convert thoughts into text using its device, offering new communication possibilities for patients with speech impairments. According to media reports, the U.S. Food and Drug Administration (FDA) has granted Neuralink an Investigational Device Exemption (IDE), allowing it to begin testing its unapproved device. DJ Seo, President of Neuralink, stated that the new trial is designed to read speech signals directly from the brain, capturing what people imagine they are saying. “If you imagine speaking, we can capture it,” he said. Neuralink currently envisions a future where healthy individuals will have its devices implanted within approximately three to four years. This technology is expected to enable humans to interact with large language model AI platforms at the speed of thought—potentially even faster than normal speech—marking a significant milestone in the commercial application of brain-computer interface technology. (Wallstreetcn)

7. R&D Design Services Accelerate the Clinical Translation of Medical Research Achievements

Medical device research and development is a complex and rigorous process involving multiple aspects, including technology, regulations, and clinical applications. Ousida boasts a 20,000-square-meter science and technology innovation center and has established a Medical Device Research Institute dedicated to the clinical translation of medical research achievements. It possesses a high-caliber, international, multidisciplinary team proficient in the entire lifecycle of R&D, regulatory affairs, clinical trials, registration, and manufacturing, capable of developing and producing various complex and innovative products. With extensive project experience and industry resources, Ousida has constructed a standardized, regulated, and digitalized full-process service system. It provides one-stop services ranging from preliminary market research, product concept generation, and product design and development to prototype production and testing. To date, more than 200 projects have entered the review stage at Ousida, with over 100 projects currently under development, achieving a 100% success rate in translation. (Compiled by Ousida)

8. Lepu Medical and Hanhai Information Reach Strategic Cooperation

Lepu Medical Announces Strategic Cooperation with Hanhai Information to Build Omni-Channel Sales Network for Aesthetic Medicine BusinessRecently, Lepu Medical announced that it had signed a "Strategic Cooperation Agreement" with Hanhai Information Technology (Shanghai) Co., Ltd. The two parties will establish a long-term and comprehensive strategic partnership to achieve resource sharing and jointly develop the aesthetic medicine business segment. Hanhai Information will be authorized to conduct market promotion and operations for the brands under Lepu Medical’s aesthetic medicine segment, providing operational solutions that include both online and offline resources. This cooperation will add new online channels to the sales network of the company’s aesthetic medicine segment, complementing its existing offline sales channels and establishing an omni-channel sales network. Hanhai Information is Meituan’s core entity in Shanghai and the legal operator of Meituan.com and Dianping.com, possessing complete independent operating rights for its platforms. (National Business Daily)